Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2021 Jan 8;24(2):532–541. doi: 10.1038/s41391-020-00311-2

Table 2. PPV performance in testing set.

Positive predictive value (PPV) of PSA testing for clinically significant prostate cancer using top 5% (PPV95) and top 20% (PPV80) cutoffs of PHS166 and PHS46 risk scores. The percent change for each metric is calculated using the value of PHS46 as the reference.

PPV PHS46 PHS166 Change (%)

PPV95 0.227 [0.159,0.292] 0.239 [0.171,0.305] 6.3 [−25.5,32.1]
PPV80 0.192 [0.155,0.231] 0.187 [0.150,0.222] −2.8 [−16.3,9.9]